Navigation Links
Professor Riccardo Lencioni Joins Delcath Systems' Scientific Advisory Board
Date:12/22/2009

NEW YORK, Dec. 22 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. (Nasdaq: DCTH), a medical technology company testing its proprietary treatment method for primary and metastatic cancers to the liver, announced today that Professor Riccardo Lencioni has joined the Company's Scientific Advisory Board, effective immediately.

"We formed our Scientific Advisory Board in 2008 to advance the development of our Delcath PHP System(TM) with insight from the leading experts in regional cancer therapies," said Eamonn Hobbs, President and CEO of Delcath. "Professor Lencioni is well known to us at Delcath. He has extensive expertise in treating liver cancers and is a pioneer in the emerging field of interventional oncology. We are confident that he will have a palpable impact on the clinical and regulatory success of our core technology, ongoing R&D, and other key scientific initiatives."

Professor Lencioni is an Associate Professor of Radiology at the University of Pisa in Italy and the Director of the Division of Diagnostic Imaging and Intervention at Pisa University Hospital. He is Chairman of the Membership Committee of the Cardiovascular and Interventional Radiological Society of Europe, and Chairman of the Programme Committee of the European Conference on Interventional Oncology. He is also a member of the Steering Committee of the World Conference on Interventional Oncology, and was a founder of the International Liver Cancer Association, in which he also acts as a member of the Governing Board. Professor Lencioni has been a Visiting Professor at 20 different European, American and Asian universities.

Professor Lencioni earned his medical degree with honors from the University of Pisa, where he is board certified in Radiology and Gastroenterology. Having completed two fellowships in Interventional Radiology, he has served as a faculty member in various residency programs, including Radiology, Surgery and Gastroenterology.

Professor Lencioni has edited seven books and has authored 135 articles in peer-reviewed international journals and 40 book chapters in textbooks of Radiology, Gastroenterology and Surgery. He has been an invited or honorary lecturer for more than 400 international meetings and conferences.

Delcath's Scientific Advisory Board now has five members. In addition to Professor Lencioni, the board includes Professor Alexander M.M. Eggermont, MD, PhD, from the Erasmus University Medical Center in The Netherlands; Doctor Douglas L. Fraker, from the University of Pennsylvania School of Medicine; Doctor Larry Kvols, from the H. Lee Moffitt Cancer Center & Research Institute in Tampa, Florida; and Doctor Leonard B. Saltz, from the Memorial Sloan-Kettering Cancer Center and the Weill College of Medicine in New York.

About Delcath Systems, Inc.

Delcath Systems Inc. is a medical device company specializing in cancer treatment. The Company is testing a proprietary, patented drug delivery system for the treatment of liver cancers. Delcath's novel drug delivery platform is testing the delivery of ultra-high doses of anti-cancer drugs to the liver while preventing these high doses of drug from entering the patient's bloodstream. The Company maintains a broad intellectual property portfolio on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company's website at www.delcath.com.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to our ability to successfully complete Phase III clinical trials and secure regulatory approval of our current or future drug-delivery system and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.

SOURCE Delcath Systems, Inc.


'/>"/>
SOURCE Delcath Systems, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. KGI Professor Ian Phillips Awarded Defense Grants for Medical Combat Research
2. Royalty Pharma Announces that Alexander von Perfall Joins Management Team
3. Howard Goldstein Joins Microchip Biotechnologies, Inc. as Executive Vice President
4. Scott Glenn Joins Exagen Diagnostics as Chairman and CEO
5. PFC Pharma Joins DATATRAKs CRO Connect Program
6. William Cork Joins Fenwal as Chief Technology Officer
7. Jeffrey Trotter Joins Pharmanet Development Group as Executive Vice President, Phase IV Development
8. Dr. Harry Kovelman Joins Ferring Pharmaceuticals as Associate Medical Director for Orthopaedics
9. American Lung Association of California Joins Sheriffs Department to Support Influenza Vaccination In Sacramento
10. Marsha Fanucci Joins Ironwood Board of Directors
11. Dr. Mahdi B. Fawzi Joins Warner Chilcott as President, Global Research and Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Research and ... Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data derived ... Assessment of major trends with potential impact on the market ... of market segmentation which comprises of sub markets, regional and ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... report to their offering. ... a favourable commercial environment for MedImmune to enter. The US ... will serve to drive considerable growth for effective anti-influenza medications. ... cap sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... MOUNTAIN VIEW, Calif. , June 23, 2016 ... 9:00 a.m. CST on Thursday, July 7, 2016 , , ... kayla.belcher@frost.com ) , , , , EXPERT PANELISTS:  ... Sciences, Nitin Naik; Senior Industry Analyst, Christi Bird; Senior Industry Analyst, ... The global pharmaceutical industry is witnessing ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension ... that it will receive two significant new grants to support its work to ... its 25th anniversary by recognizing patients, medical professionals and scientists for their work ...
(Date:6/24/2016)... ... , ... Comfort Keepers® of San Diego, CA is excited to announce they ... to drive cancer patients to and from their cancer treatments. Comfort Keepers provides ... life and ongoing independence. Getting to and from medical treatments is one of ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented its first-ever ... Medicine conference in Ponte Vedra Beach, FL. The awards honor the outstanding work ... Practice and Pediatric Emergency Medicine Practice. , “With this award, we recognize ...
(Date:6/24/2016)... ... 2016 , ... Strategic Capital Partners, LLC (SCP) in concert ... capital for emerging technology companies. SCP has delivered investment events and professional ... than a million dollars of capital investment for five companies. The ...
(Date:6/24/2016)... ... 2016 , ... Today, MTI-GlobalStem, a provider of optimized transfection ... to transfect cells, announces its launch of the PluriQ™ G9™ Gene Editing System ... is a complete system for culturing and transfecting human pluripotent stem cells for ...
Breaking Medicine News(10 mins):